LincSwitch Therapeutics develops therapeutics based on long non-coding RNA (lncRNA) technology. The company focuses on modulating gene expression to target and correct disease-causing genetic pathways. This approach aims to provide novel therapeutic interventions for various conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases, including cancer, metabolic disorders, and inflammatory diseases, are driven by the aberrant expression of specific genes. Traditional therapeutic approaches often lack the precision to selectively target these disease-causing genes without affecting other essential cellular processes.
Solution
This startup is developing a new class of therapeutics based on long non-coding RNAs (lncRNAs). These lncRNA-based therapeutics are designed to selectively target and modulate the expression of disease-causing genes at the RNA level. By harnessing the natural regulatory potential of lncRNAs, the company aims to create highly specific interventions that address the underlying genetic mechanisms of complex diseases, offering a more targeted approach compared to traditional methods. This approach has the potential to minimize off-target effects and improve therapeutic outcomes.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapies for cancer, metabolic disorders, and inflammatory diseases.
Features
- lncRNA-based therapeutics designed for high target specificity
- Modulation of gene expression at the RNA level
- Potential for reduced off-target effects compared to traditional therapies
- Focus on cancer, metabolic disorders, and inflammatory diseases